KLK6

(redirected from hK6)
Also found in: Acronyms.

KLK6

A gene on chromosome 19q13.3 that encodes a serine protease that catalyses amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins (such as fibronectin, laminin, vitronectin and collagen). It may be involved in regulating axon outgrowth following spinal cord injury. KLK6 may play a role in invasion and metastasis.

Molecular pathology
KLK6 degrades alpha-synuclein, preventing its polymerisation, suggesting a role in the pathogenesis of Parkinson disease and other synucleinopathies.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
We measured hK5, hK6, and hK11 by sandwich-type ELISA, 96-well plates, as described earlier (19-21) with use of biotinylated detection antibodies, alkaline phosphatase-conjugated streptavidin and diflunisal phosphate substrate.
This hormonal intervention produced a significant up-regulation of serum hK2, hK3, hK5, hK6, hK7, and hK10 concentrations, with the most profound impact on hK2 and hK3.
We found significant correlations between serum concentrations of hK2 and hK3 (positive) or hK10 (negative), between hK4 and hK13 or hK14 (both positive), between hK5 and hK6 (positive), and between hK7 and hK8, hK13, or hK14 (all positive).
In view of the encouraging results, the Board of Directors recommended the payment of an interim dividend of HK6 cents per share (2016 Interim: nil).
Because the hK4, hK6, hK8, and hK11 proteins are produced by more restricted tissues (12, 21-23), hK7 might play more general roles than other human kallikreins, including the degradation of adhesion molecules between cells (24).
The Board proposed an interim dividend of HK6.0 cents per ordinary share for the six months ended 30 June 2015.
hK6 is recognized as a serine protease because the amino acid residues known to be crucial for substrate binding, specificity, and catalysis of the serine proteases (including serine, histidine, and aspartic acid) are highly conserved (5-8).
The board declared a final dividend of HK6.0 cents per ordinary share.
Recently, three other members of this family, hK6 (also known as neurosin), hK10 [also known as normal epithelial cell specific 1 (NES1)], and hK11 [also known as trypsin-like serine protease (TLSP)], have been shown to be potential biomarkers for ovarian and prostate cancer (4-6).
The Board proposed to pay a final dividend of HK6.7 cents per share.